Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Wataru Munakata,Koji Izutsu,Yuko Mishima,Hirokazu Nagai,Yuko Ishihara,Junji Suzumiya,Yuzuru Kanakura,Toshihiro Nanki, Takeshi Miyake,Atsuko Kawasaki,Tatsuya Yoshinaga,Kenichi Ishizawa

Japanese journal of clinical oncology（2023）

引用 0|浏览7

暂无评分

摘要

This study demonstrated that mosunetuzumab has an acceptable safety profile and antitumor activity in Japanese patients with relapsed/refractory B-cell NHL. The recommended Phase II dose of 1.0/2.0/60.0/60.0/30.0 mg was tolerable and there were no new or different safety signals compared with the global Phase I study.

查看译文

关键词

non-Hodgkin lymphoma, Japan, Administration, intravenous, antibodies, bispecific, administration and dosage, adverse effects

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要